Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment. Check your account now to learn when your revalidation is due. More information here.

Tailored Care Management for Williams & Colbert Class Members: Register to attend Aug. 4 virtual listening session

Drugs and Therapeutics (D & T) Committee Meeting Results for: September 14, 2016

Drugs and Therapeutics (D & T) Committee Meeting Results September 14, 2016
Drug Name	Review Type	Committee Recommendation	Prior Approval Status – Final Determination
Viekira XR	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Epclusa	New Drug Initial Review	Preferred with a Prior Approval	Preferred with a Prior Approval
Ocaliva	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Briviact	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Xtampza ER	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Adzenys XR-ODT	New Drug Initial Review	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)
Spinosad	New Drug Initial Review	Remove Prior Approval (Preferred)	Prior Approval Removed (Preferred)
Orenitram ER	New Drug Appeal	Require Prior Approval (Non-Preferred)	Prior Approval Required (Non-Preferred)

Drugs and Therapeutics (D & T) Committee